Clarius Group LLC’s Recursion Pharmaceuticals RXRX Stock Holding History

Clarius Group LLC’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$117K	Hold	28,601	–	–	0.01%	378
2025 Q3	$140K	Hold	28,601	–	–	0.01%	391
2025 Q2	$145K	Hold	28,601	–	–	0.01%	465
2025 Q1	$151K	Hold	28,601	–	–	0.01%	468
2024 Q4	$193K	Hold	28,601	–	–	0.01%	433
2024 Q3	$188K	Hold	28,601	–	–	0.01%	435
2024 Q2	$215K	Hold	28,601	–	–	0.02%	400
2024 Q1	$285K	Hold	28,601	–	–	0.02%	346
2023 Q4	$282K	Hold	28,601	–	–	0.02%	369
2023 Q3	$219K	Hold	28,601	–	–	0.02%	419
2023 Q2	$214K	Hold	28,601	–	–	0.02%	477
2023 Q1	$191K	Hold	28,601	–	–	0.02%	484
2022 Q4	$221K	Hold	28,601	–	–	0.02%	463
2022 Q3	$304K	Hold	28,601	–	–	0.03%	341
2022 Q2	$233K	Buy	28,601 +15,001	+110%	+$100K	0.02%	402
2022 Q1	$233K	Hold	13,600	–	–	0.02%	436
2021 Q4	$233K	Buy	+13,600	New	+$256K	0.02%	436

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Clarius Group LLC's RXRX Position: Q4 2025 in Review

Clarius Group LLC held its Recursion Pharmaceuticals (RXRX) position steady in Q4 2025 at 28,601 shares worth $117K. The position accounts for 0.01% of the portfolio, ranked #378.

Clarius Group LLC first reported a position in RXRX in Q4 2021 and has held it in 17 quarters since. The position peaked at $304K in Q3 2022. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Clarius Group LLC held 28,601 shares of Recursion Pharmaceuticals worth $117K as of Q4 2025.
Clarius Group LLC left its Recursion Pharmaceuticals share count unchanged in Q4 2025.
Recursion Pharmaceuticals made up 0.01% of Clarius Group LLC's portfolio in Q4 2025, its #378 holding.
Clarius Group LLC first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 17 quarters since.
Clarius Group LLC's Recursion Pharmaceuticals position peaked at $304K in Q3 2022.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.